STIM1-VHL Fusion FISH Probe
The STIM1-VHL Fusion FISH Probe is used to confirm a fusion of the STIM1 and VHL genes. The fusion of the STIM1 and VHL genes has been associated with Lung Squamous Cell Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use.
SKU | Test Kits | Buffer | Dye Color | Order Now |
---|---|---|---|---|
STIM1-VHL-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-RERE | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-REOR | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-REGO | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-REGR | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-REAQ | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-ORRE | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-OROR | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-ORGO | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-ORAQ | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-GORE | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-GOOR | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-GOGO | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-GOGR | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-GOAQ | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-GRRE | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-GROR | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-GRGO | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-GRGR | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-GRAQ | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-AQRE | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-AQOR | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-AQGO | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-AQGR | 20 (40 μL) | 200 μL | ||
STIM1-VHL-20-AQAQ | 20 (40 μL) | 200 μL |
STIM1 Gene Summary
This gene encodes a type 1 transmembrane protein that mediates Ca2+ influx after depletion of intracellular Ca2+ stores by gating of store-operated Ca2+ influx channels (SOCs). It is one of several genes located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocrotical carcinoma, and lung, ovarian, and breast cancer. This gene may play a role in malignancies and disease that involve this region, as well as early hematopoiesis, by mediating attachment to stromal cells. Mutations in this gene are associated with fatal classic Kaposi sarcoma, immunodeficiency due to defects in store-operated calcium entry (SOCE) in fibroblasts, ectodermal dysplasia and tubular aggregate myopathy. This gene is oriented in a head-to-tail configuration with the ribonucleotide reductase 1 gene (RRM1), with the 3' end of this gene situated 1.6 kb from the 5' end of the RRM1 gene. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2013]
Gene Name: Stromal Interaction Molecule 1
Chromosome: CHR11: 3876932 -4114440
Locus: 11p15.4
VHL Gene Summary
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]
Gene Name: Von Hippel-Lindau Tumor Suppressor
Chromosome: CHR3: 10183318 -10195354
Locus: 3p25.3
Gene Diseases
The STIM1 VHL Fusion has been associated with the following diseases:
Disease Name |
---|
Lung Squamous Cell Carcinoma |
FISH Probe Protocols
Protocol, Procedure, or Form Name | Last Modified | Download |
---|